Harvard’s Christopher P. Cannon, MD — On Anacetrapib, And DEFINE’s Meaning

. . . . Primary Results of the DEFINE trial: Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib.
. . .

I suppose I should label this the “equal time” portion of our broadcast — to pair it off, with Ms. Mendes’ silly clip, much below.

More seriously, the key points here are the unknowns, as even Dr. Cannon candidly volunteers. Will the results be borne out in the 30,000 patient trial? And if so, when? We shall see.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s